EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control

  Рет қаралды 648

European Association for the Study of Diabetes

European Association for the Study of Diabetes

Күн бұрын

Пікірлер: 1
@maxra1
@maxra1 8 ай бұрын
SGLT2 inhibitors are a good drug for prevention for non diabetic and with normal heart and kidney status?
GLP-1 Agonists: Wonder Drugs of the 21st Century?
50:30
The Aspen Institute
Рет қаралды 4,8 М.
What are SGLT2 inhibitors and how do they affect kidney disease?
10:55
Plant Based Kidney Health
Рет қаралды 12 М.
They Chose Kindness Over Abuse in Their Team #shorts
00:20
I migliori trucchetti di Fabiosa
Рет қаралды 12 МЛН
How Much Tape To Stop A Lamborghini?
00:15
MrBeast
Рет қаралды 188 МЛН
Cardiovascular Benefits of GLP-1 RAs
26:15
American Heart Association
Рет қаралды 1,9 М.
EASD 2023 - Health benefits from cold exposure
13:56
European Association for the Study of Diabetes
Рет қаралды 84
EASD 2023 - Charna Dibner and Frank Scheer discussing the impact of circadian rhythms on diabetes
15:37
European Association for the Study of Diabetes
Рет қаралды 175
Basic Mechanisms of SGLT2 inhibitors in the Kidney
12:43
AHAScience
Рет қаралды 900
EASD 2024 - Diabetes remission - is type 2 diabetes reversible?
12:26
European Association for the Study of Diabetes
Рет қаралды 12
EASD 2023 - Andrew Frankel and Daniel van Raalte debating SGLT-2 inhibition for diabetes and CKD
12:39
European Association for the Study of Diabetes
Рет қаралды 129
Navigating GLP-1 agonists | DoM Grand Rounds | 17 January 2024
1:07:25
Stanford Department of Medicine
Рет қаралды 6 М.